GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 with the slogan "Targeting Ultra-Rapid, Durable Remissions In Depression". The company focuses on transforming the treatment of psychiatric and neurological disorders. GH Research recently secured a significant $125.00M Series B investment on 12 April 2021. The investment was led by a consortium of prominent investors including RA Capital Management, Boxer Capital, Acuta Capital, BVF Partners, Cormorant Asset Management, Logos Capital, RTW Investments, Verition Fund Management, Venrock Healthcare Capital Partners, and Surveyor Capital. GH Research operates in the Biopharma, Biotechnology, and Pharmaceutical industries.
GH Research plc
Targeting Ultra-Rapid, Durable Remissions In Depression (NASDAQ: GHRS)
Founded 2018
50 employees
Series B
Total: $125.00M
Biopharma, Biotechnology +1
General Information
Company Name
GH Research plc
Founded Year
2018
Employees
50
Industries
Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Series B
BounceWatch is an independent company data service, not affiliated with GH Research plc. To contact GH Research plc, visit ghres.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
About GH Research plc
Taxonomy: Biopharmaceuticals, Neurological conditions, Psychiatric conditions, Therapy, Revolutionize, Depression, Ultra-Rapid Remissions, Durable Remissions, Start-up, NASDAQ, GH Research, Investment, Innovation, Research and Development
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series B | $125.00M | 10 |
|
12 Apr 2021 |
Latest News
View All
GH Research plc Alternatives & Competitors
View All Alternatives
GH Research plc vs
Acticor Biotech
France
To treat the acute phase of ischemic stroke !
Post-IPO Equity
18 employees
Biopharma, Biotechnology
GH Research plc vs
Vistagen
United States
Changing the trajectory of mental health care – One Mind at a Time
Post-IPO Equity
58 employees
Biotechnology, Pharmaceutical
GH Research plc vs
Candid Therapeutics
United States
Developing innovative therapeutics that can materially improve the lives of patients
Acquired
46 employees
Biotechnology, Pharmaceutical
FAQ About GH Research plc
Targeting Ultra-Rapid, Durable Remissions In Depression (NASDAQ: GHRS)
GH Research plc was founded in 2018.
GH Research plc operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Biopharmaceuticals, Neurological conditions, Psychiatric conditions and Therapy.
GH Research plc has approximately 50 employees.
GH Research plc has completed 1 funding round, raising a total of $125.00M. The latest funding stage is Series B.
Top alternatives and competitors to GH Research plc include Acticor Biotech, Vistagen, Candid Therapeutics, Hua Medicine, Tetherex Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GH Research plc and Acticor Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for GH Research plc, https://bouncewatch.com/company/gh-research, updated 29 December 2024. When citing, please name BounceWatch and link this page.
